Cardiac Sarcomere Activation and its Therapeutic Application in Heart Failure

2017 ◽  
pp. 109-123 ◽  
Author(s):  
Antonio Romero ◽  
Bradley P. Morgan
Keyword(s):  
Heart Failure ◽  
Therapeutic Application ◽  
Cardiac Sarcomere

Therapeutic application of prazosin in chronic refractory congestive heart failure

1981 ◽  
Vol 71 (1) ◽  
pp. 153-160 ◽  
Author(s):  
Najam A. Awan ◽  
Kathleen E. Needham ◽  
Mark K. Evenson ◽  
Ezra E. Amsterdam ◽  
Dean T. Mason
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Therapeutic Application

Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure

1978 ◽  
Vol 65 (1) ◽  
pp. 146-154 ◽  
Author(s):  
Najam A. Awan ◽  
Richard R. Miller ◽  
Mark P. Miller ◽  
Kristin Specht ◽  
Zakauddin Vera ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Pharmacology ◽  
Congestive Heart Failure ◽  
Therapeutic Application

scholarly journals Adrenomedullin in heart failure: pathophysiology and therapeutic application

2018 ◽  
Vol 21 (2) ◽  
pp. 163-171 ◽  
Author(s):  
Adriaan A. Voors ◽  
Daan Kremer ◽  
Christopher Geven ◽  
Jozine M. ter Maaten ◽  
Joachim Struck ◽  
...  
Keyword(s):  
Heart Failure ◽  
Therapeutic Application

Dapagliflozin for heart failure – is it a class effect?

2020 ◽  
Author(s):  
Gerard Marshall Raj ◽  
Mukta Wyawahare
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Therapeutic Application ◽  
Glucose Lowering ◽  
Reduced Ejection Fraction ◽  
Beneficial Effects

Dapagliflozin, an SGLT2 inhibitor used in the management of Type 2 diabetes mellitus, has been recently approved for the control of worsening cardiovascular events, including deaths and hospitalizations, in adults with heart failure with reduced ejection fraction. Previously, canagliflozin had a label change with regards to its additional usage in the reduction of risk of hospitalization for heart failure in patients with both Type 2 diabetes mellitus and diabetic nephropathy with albuminuria. On the other hand, the therapeutic application of empagliflozin and ertugliflozin in heart failure is yet to be delineated comprehensively. The beneficial effects of these SGLT2 inhibitors, dapagliflozin in particular, in heart failure are found to be independent of neither the glucose-lowering nor the SGLT2 inhibiting effects.

scholarly journals Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application

2018 ◽  
Vol 32 (6) ◽  
pp. 617-624 ◽  
Author(s):  
S. Bouchez ◽  
F. Fedele ◽  
G. Giannakoulas ◽  
F. Gustafsson ◽  
V.-P. Harjola ◽  
...  
Keyword(s):  
Heart Failure ◽  
Advanced Heart Failure ◽  
Therapeutic Application

Mitochondria in Cardiomyopathy: Alterations in Size, Number and Internal Structures

1968 ◽  
Vol 26 ◽  
pp. 126-127
Author(s):  
George Hug ◽  
William K. Schubert
Keyword(s):  
Heart Failure ◽  
Biochemical Analysis ◽  
Left Ventricular ◽  
Size Number ◽  
Internal Structures ◽  
Left Ventricular Outflow ◽  
Chest X Ray ◽  
Myocardial Fibers ◽  
Muscle Biopsies ◽  
Needle Liver Biopsy

A white boy six months of age was hospitalized with respiratory distress and congestive heart failure. Control of the heart failure was achieved but marked cardiomegaly, moderate hepatomegaly, and minimal muscular weakness persisted.At birth a chest x-ray had been taken because of rapid breathing and jaundice and showed the heart to be of normal size. Clinical studies included: EKG which showed biventricular hypertrophy, needle liver biopsy which showed toxic hepatitis, and cardiac catheterization which showed no obstruction to left ventricular outflow. Liver and muscle biopsies revealed no biochemical or histological evidence of type II glycogexiosis (Pompe's disease). At thoracotomy, 14 milligrams of left ventricular muscle were removed. Total phosphorylase activity in the biopsy specimen was normal by biochemical analysis as was the degree of phosphorylase activation. By light microscopy, vacuoles and fine granules were seen in practically all myocardial fibers. The fibers were not hypertrophic. The endocardium was not thickened excluding endocardial fibroelastosis. Based on these findings, the diagnosis of idiopathic non-obstructive cardiomyopathy was made.

Localization of endothelial nitric oxide synthase in the normal and failing human atrial myocardium

1996 ◽  
Vol 54 ◽  
pp. 786-787
Author(s):  
Chi-Ming Wei ◽  
Margarita Bracamonte ◽  
Shi-Wen Jiang ◽  
Richard C. Daly ◽  
Christopher G.A. McGregor ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Nitric Oxide Synthase ◽  
Endothelial Nitric Oxide Synthase ◽  
Cardiac Tissues ◽  
Mammalian Tissues ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also may modulate cardiomyocyte inotropism and growth via increasing cGMP. While endothelial nitric oxide synthase (eNOS) isoforms have been detected in non-human mammalian tissues, expression and localization of eNOS in the normal and failing human myocardium are poorly defined. Therefore, the present study was designed to investigate eNOS in human cardiac tissues in the presence and absence of congestive heart failure (CHF).Normal and failing atrial tissue were obtained from six cardiac donors and six end-stage heart failure patients undergoing primary cardiac transplantation. ENOS protein expression and localization was investigated utilizing Western blot analysis and immunohistochemical staining with the polyclonal rabbit antibody to eNOS (Transduction Laboratories, Lexington, Kentucky).

Sign in / Sign up

Export Citation Format

Share Document